PriceTargets.com logo

Haleon - HLN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.95
  • Forecasted Upside: 13.00%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 4 Buy Ratings
  • 1 Strong Buy Ratings
$9.69 As of 12/20/2024 05:33 PM ET
▼ -0.01 (-0.10%)

This chart shows the closing price for HLN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Haleon Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HLN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HLN

Analyst Price Target is $10.95
▲ +13.00% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Haleon in the last 3 months. The average price target is $10.95, with a high forecast of $10.95 and a low forecast of $10.95. The average price target represents a 13.00% upside from the last price of $9.69.

This chart shows the closing price for HLN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Haleon. This rating has held steady since September 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 1 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/1/2024UBS GroupUpgradeStrong-Buy
9/20/2024Morgan StanleyBoost TargetOverweight ➝ Overweight$9.90 ➝ $10.95
8/6/2024Berenberg BankInitiated CoverageBuy
8/6/2024The Goldman Sachs GroupDowngradeBuy ➝ Neutral
6/5/2024Berenberg BankInitiated CoverageBuy
4/17/2024HSBCInitiated CoverageBuy
3/26/2024ArgusReiterated RatingBuy ➝ Buy
11/1/2023Morgan StanleyInitiated CoverageOverweight
8/8/2023InvestecUpgradeSell ➝ Hold
5/24/2023Stifel NicolausInitiated CoverageHold
4/6/2023ArgusUpgradeHold ➝ Buy
4/4/2023Sanford C. BernsteinInitiated CoverageOutperform
2/23/2023InvestecInitiated CoverageSell
1/31/2023BarclaysBoost TargetGBX 360 ➝ GBX 364
1/6/2023Morgan StanleyUpgradeEqual Weight ➝ Overweight
12/7/2022BarclaysUpgradeEqual Weight ➝ Overweight
11/11/2022BarclaysLower TargetGBX 347 ➝ GBX 298
9/28/2022ArgusInitiated CoverageHold
8/19/2022Morgan StanleyInitiated CoverageEqual Weight
8/15/2022Royal Bank of CanadaInitiated CoverageSector Perform
7/29/2022Deutsche Bank AktiengesellschaftInitiated CoverageHold
7/25/2022The Goldman Sachs GroupInitiated CoverageBuy
7/25/2022Credit Suisse GroupInitiated CoverageOutperform
7/25/2022Bank of AmericaInitiated CoverageBuy
7/25/2022BarclaysInitiated CoverageEqual Weight
7/25/2022Jefferies Financial GroupInitiated CoverageHold
7/25/2022JPMorgan Chase & Co.Initiated CoverageUnderweight
7/25/2022CitigroupInitiated CoverageBuy
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.27 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 9 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 12 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 13 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 13 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 13 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 14 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 20 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 20 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Haleon logo
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Read More

Today's Range

Now: $9.69
Low: $9.60
High: $9.77

50 Day Range

MA: $9.72
Low: $9.24
High: $10.13

52 Week Range

Now: $9.69
Low: $7.89
High: $10.80

Volume

5,796,123 shs

Average Volume

5,450,907 shs

Market Capitalization

$43.86 billion

P/E Ratio

28.50

Dividend Yield

1.08%

Beta

0.28

Frequently Asked Questions

What sell-side analysts currently cover shares of Haleon?

The following equities research analysts have issued research reports on Haleon in the last twelve months: Argus, Berenberg Bank, HSBC Holdings plc, Morgan Stanley, The Goldman Sachs Group, Inc., and UBS Group AG.
View the latest analyst ratings for HLN.

What is the current price target for Haleon?

0 Wall Street analysts have set twelve-month price targets for Haleon in the last year. Their average twelve-month price target is $10.95, suggesting a possible upside of 13.0%. Morgan Stanley has the highest price target set, predicting HLN will reach $10.95 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $10.95 for Haleon in the next year.
View the latest price targets for HLN.

What is the current consensus analyst rating for Haleon?

Haleon currently has 1 hold rating, 4 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HLN will outperform the market and that investors should add to their positions of Haleon.
View the latest ratings for HLN.

What other companies compete with Haleon?

Other companies that are similar to Haleon include Unilever, Kenvue, SharkNinja, e.l.f. Beauty and Coty. Learn More about companies similar to Haleon.

How do I contact Haleon's investor relations team?

The company's listed phone number is 44-19-3282-2000 and its investor relations email address is [email protected]. The official website for Haleon is www.haleon.com. Learn More about contacing Haleon investor relations.